Term ends Oct 23, 2039 · High confidence
20-year base term ends Oct 23, 2039
Held by Step Pharma S.A.S
Filed Apr 16, 2024 as application 18/636,731 · Granted Jul 29, 2025
Base term, 20 years from filing
Today
2019
2039
Clock starts
Oct 23, 2019
Oct 23, 2019
Term ends
Oct 23, 2039
Oct 23, 2039
Granted
Jul 29, 2025
Jul 29, 2025
base term
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 23, 2019, when application PCT/EP2019/078848, the earliest non-provisional in its chain, was filed (this one was filed Apr 16, 2024) | Oct 23, 2039 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 23, 2039 | High confidence |
This family
| US 11,987,573 | In force May 2041 | May 2041 |
| US 12,371,419 | this patent Oct 2039 | Oct 2039 |
| Application 19/217,739 | Pending not computed | not computed |
3 of 4 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 21, 2025 Reel 71180, frame 760 | Sygnature Discovery Limited | Step Pharma S.A.S. | Assignment of Assignor's Interest |
| Oct 16, 2026 Reel 76729, frame 546 | George, Pascal | Step Pharma S.A.S | Assignment of Assignor's Interest |
| Oct 16, 2026 Reel 76729, frame 811 | Quddus, Abdul; Novak, Andrew; Cousin, David; Blackham, Emma; Wrigglesworth, Joseph; Duffy, Lorna; Ahmed, Saleh; Jones, Geraint; Birch, Louise | Sygnature Discovery Limited | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2039
Term ends Oct 23, 2039. Maintenance fees still fall due before then
Citations
2
later US patents cite this one
Fewer than half of the utility patents granted in 2025 in our data have been cited yet, so we show the count and do not rank on it.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.